Compare TWLO & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWLO | RMD |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | United States | United States |
| Employees | 5587 | 10600 |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8B | 28.4B |
| IPO Year | N/A | N/A |
| Metric | TWLO | RMD |
|---|---|---|
| Price | $192.32 | $201.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 10 |
| Target Price | $151.54 | ★ $292.56 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.13% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.44 | $10.60 |
| Revenue Next Year | $8.21 | $7.41 |
| P/E Ratio | $526.76 | ★ $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $91.84 | $180.27 |
| 52 Week High | $238.48 | $293.81 |
| Indicator | TWLO | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 49.48 |
| Support Level | $179.78 | $182.46 |
| Resistance Level | $202.50 | $260.21 |
| Average True Range (ATR) | 10.13 | 5.43 |
| MACD | -2.89 | -0.74 |
| Stochastic Oscillator | 31.15 | 33.95 |
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.